".....we were delighted to report positive preclinical data on the ability of PAT-DX3 to be used for synthetic lethality strategies which, along with its potential for the delivery of therapeutic payloads into the cell and cell nucleus, remains an area of high interest with potential partners.”
Ann: Appendix 4C - Quarterly - 31 March 2023, page-2
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $18.51M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 654316 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 1586680 | 3 |
View Market Depth
| Last trade - 10.06am 08/05/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable